中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (22): 4028-4031.doi: 10.3969/j.issn.1673-8225.2011.22.010

• 人工假体 artificial prosthesis • 上一篇    下一篇

髋关节置换后利伐沙班与低分子肝素预防下肢深静脉血栓的比较

靖光武1，2，叶树楠2，杨述华2   

  1. 1江汉大学附属医院骨科，湖北省武汉市  430015
    2华中科技大学附属同济医学院协和医院骨科，湖北省武汉市430022
  • 收稿日期:2010-12-19 修回日期:2011-03-17 出版日期:2011-05-28 发布日期:2011-05-28
  • 作者简介:靖光武★，男，1976年生，湖北省潜江市人，汉族，华中科技大学附属同济医学院协和医院在读硕士，主治医师，主要从事关节、创伤外科方面的研究。 jingguangwu@yahoo.cn

Curative effect of rivaroxaban versus low molecular weight heparin to prevent deep venous thrombosis following total hip arthroplasty

Jing Guang-wu1,2, Ye Shu-nan2,Yang Shu-hua2   

  1. 1Department of Orthopedics, Affiliated Hospital of Jianghan University, Wuhan  430015, Hubei Province, China
    2Department of Orthopedics, Union Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan  430022, Hubei Province, China
  • Received:2010-12-19 Revised:2011-03-17 Online:2011-05-28 Published:2011-05-28
  • About author:Jing Guang-wu★, Studying for master’s degree, Attending physician, Department of Orthopedics, Affiliated Hospital of Jianghan University, Wuhan 430015, Hubei Province, China; Department of Orthopedics, Union Hospital of Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430022, Hubei Province, China jingguangwu@yahoo.cn

PDF

583

被引次数

90

摘要：

背景：低分子肝素可显著降低髋关节置换后下肢深静脉血栓的发生率，但其因需皮下注射而存在局限性。
目的：比较全髋关节置换后应用利伐沙班与低分子肝素预防下肢深静脉血栓疗效和安全性的差异。
方法：58例全髋关节置换患者按随机数字表法分为2组，利伐沙班组28例，低分子肝素组(达肝素)30例。置换后行双下肢彩色多普勒检查评估DVT形成情况，并观察治疗期间出血情况。
结果与结论：利伐沙班组与达肝素组患者在预防下肢深静脉血栓疗效上差异无显著性意义(P > 0.05)。两组在治疗期间均无严重出血，置换后非严重出血差异也无显著性意义(P > 0.05)。提示利伐沙班在预防全髋置换后下肢深静脉血栓的疗效与安全性上与低分子肝素作用相当。

关键词: 利伐沙班, 全髋关节置换, 下肢深静脉血栓, 低分子肝素, 安全性

Abstract:

BACKGROUND: Low molecular weight heparin can obviously reduce the incidence of deep venous thrombosis (DVT) following total hip arthroplasty (THA). However, subcutaneous injection limits the application of low molecular weight heparin.
OBJECTIVE: To observe the clinical effects and security of low molecular weight heparin and rivaroxaban against DVT after THA.
METHODS: Totally 58 THA patients were randomized into two groups: rivaroxaban group with 28 cases and heparin group with 30 cases. Occurrence of DVT and bleeding were observed under color Doppler of lower limbs.
RESULTS AND CONCLUSION: There was no statistics differences in DVT prevention and intraoperative bleeding between the two groups (P < 0.05). Rivaroxaban has similar effects to low molecular weight heparin on DVT prevention after THA.

中图分类号: